STAAART SmarT Abdominal Aortic AneuRysm Treatment World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigm
- Coordinator
- Angiolutions GmbH, Germany
- Runs
- 1 January 2024 to 31 December 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.0m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190150530
What the project is doing
In the project's own words, from its summary on CORDIS.
The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta. Angiolutions’ award-winning & patent-protected solution leverages a fundamentally new understanding of AAA growth discovered by the founders at Stanford University. They showed that stiffness gradients between the compliant (healthy) aorta and the adjacent stiff (diseased) aneurysm serve as a motor for AAA growth.
Based on this principle & together with key physicians, we developed a minimally-invasive, non-active aortic implant (class III). The nitinol-based device is positioned adjacent to the aneurysm sack via simple, catheter-based implantation. It is specifically designed to focally increase aortic stiffness in the compliant AAA neck region, thereby reducing stiffness gradients towards the stiff AAA sack that drive aneurysm growth.
Hereby, we achieve a fast, low-risk, size-stabilizing treatment of small AAA.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Angiolutions GmbH | Hannover | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI